MCID: PRN039
MIFTS: 41

Paraneoplastic Syndromes

Categories: Cancer diseases, Immune diseases, Neuronal diseases

Aliases & Classifications for Paraneoplastic Syndromes

MalaCards integrated aliases for Paraneoplastic Syndromes:

Name: Paraneoplastic Syndromes 54 55 73

Classifications:



External Ids:

UMLS 73 C0030472

Summaries for Paraneoplastic Syndromes

NINDS : 54 Paraneoplastic syndromes are a group of rare disorders that are triggered by an abnormal immune system response to a cancerous tumor known as a "neoplasm." Paraneoplastic syndromes are thought to happen when cancer-fighting antibodies or white blood cells (known as T cells) mistakenly attack normal cells in the nervous system. These disorders typically affect middle-aged to older people and are most common in individuals with lung, ovarian, lymphatic, or breast cancer. Neurologic symptoms generally develop over a period of days to weeks and usually occur prior to the tumor being discovered. These symptoms may include difficulty in walking or swallowing, loss of muscle tone, loss of fine motor coordination, slurred speech, memory loss, vision problems, sleep disturbances, dementia, seizures, sensory loss in the limbs, and vertigo or dizziness. Paraneoplastic syndromes include Lambert-Eaton myasthenic syndrome, stiff-person syndrome, encephalomyelitis, myasthenia gravis, cerebellar degeneration, limbic or brainstem encephalitis, neuromyotonia, opsoclonus, and sensory neuropathy.

MalaCards based summary : Paraneoplastic Syndromes is related to poems syndrome and peritonitis, and has symptoms including paraneoplastic opsoclonus ataxia An important gene associated with Paraneoplastic Syndromes is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are NF-KappaB Family Pathway and Immune response IFN alpha/beta signaling pathway. The drugs Mitoxantrone and Interferon beta-1a have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and colon, and related phenotype is integument.

Wikipedia : 76 A paraneoplastic syndrome is a syndrome (a set of signs and symptoms) that is the consequence of cancer... more...

Related Diseases for Paraneoplastic Syndromes

Diseases related to Paraneoplastic Syndromes via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 364)
# Related Disease Score Top Affiliating Genes
1 poems syndrome 32.0 IL1B IL6
2 peritonitis 31.4 IL1B IL6
3 adult-onset still's disease 29.8 IL1B IL6
4 oncogenic osteomalacia 29.8 FGF23 PTHLH
5 synovitis 29.5 IL1B IL6
6 esophagitis 29.3 IL1B IL6
7 gastroenteritis 29.3 IL1B IL6
8 paraneoplastic cerebellar degeneration 11.5
9 lambert-eaton myasthenic syndrome 11.3
10 adenoma 11.3
11 autoimmune encephalitis 11.3
12 carcinoid syndrome 11.3
13 multicentric reticulohistiocytosis 11.0
14 leiomyoma 11.0
15 leiomyomatosis 11.0
16 vipoma 11.0
17 adrenal adenoma 11.0
18 pancreatic cholera 11.0
19 small cell carcinoma of the bladder 11.0
20 wdha syndrome 11.0
21 lung cancer 10.4
22 small cell cancer of the lung 10.1
23 lymphoma 10.1
24 renal cell carcinoma, nonpapillary 10.1
25 neutrophilia, hereditary 10.1 IL6 PTHLH
26 squamous cell carcinoma 10.1
27 iron deficiency anemia 10.1 FGF23 IL6
28 metaphyseal chondrodysplasia, jansen type 10.1 FGF23 PTHLH
29 dermatomyositis 10.1
30 thymoma 10.1
31 parathyroid gland disease 10.1 FGF23 PTHLH
32 mineral metabolism disease 10.0 FGF23 PTHLH
33 breast cancer 10.0
34 hepatocellular carcinoma 10.0
35 ovarian cancer 10.0
36 adenocarcinoma 10.0
37 hypoparathyroidism 10.0 FGF23 PTHLH
38 recurrent corneal erosion 10.0 IL1B IL6
39 bagassosis 10.0 IL1B IL6
40 periodontitis, chronic 10.0 IL1B IL6
41 periodontitis 10.0 IL1B IL6
42 uremic pruritus 10.0 IL1B IL6
43 glossitis 10.0 IL1B IL6
44 laryngitis 10.0 IL1B IL6
45 funisitis 10.0 IL1B IL6
46 euthyroid sick syndrome 10.0 IL1B IL6
47 acute vascular insufficiency of intestine 10.0 IL1B IL6
48 osteosclerotic myeloma 10.0 IL1B IL6
49 periapical periodontitis 10.0 IL1B IL6
50 central nervous system vasculitis 10.0 IL1B IL6

Graphical network of the top 20 diseases related to Paraneoplastic Syndromes:



Diseases related to Paraneoplastic Syndromes

Symptoms & Phenotypes for Paraneoplastic Syndromes

UMLS symptoms related to Paraneoplastic Syndromes:


paraneoplastic opsoclonus ataxia

MGI Mouse Phenotypes related to Paraneoplastic Syndromes:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 8.92 FGF23 IL1B IL6 PTHLH

Drugs & Therapeutics for Paraneoplastic Syndromes

Drugs for Paraneoplastic Syndromes (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 115)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
2
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
3
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
4
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
5 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
6 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
8 Topoisomerase Inhibitors Phase 4,Phase 2
9 Analgesics Phase 4
10 Interferon-beta Phase 4
11 Antiviral Agents Phase 4,Phase 2
12 Anti-Infective Agents Phase 4,Phase 2
13 Adjuvants, Immunologic Phase 4
14 interferons Phase 4,Phase 2
15 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2
16 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2
17 Antacids Phase 4,Phase 3,Phase 2
18
Zoledronic acid Approved Phase 3,Phase 1,Phase 2,Not Applicable 118072-93-8 68740
19
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
20
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
21
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
22
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
23
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
24
4-Aminopyridine Approved Phase 3,Phase 2,Not Applicable 504-24-5 1727
25
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7 4594 9579578
26
Cyclophosphamide Approved, Investigational Phase 3 6055-19-2, 50-18-0 2907
27
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
29
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
30 Ibandronic acid Phase 3
31 Bone Density Conservation Agents Phase 3,Phase 1,Phase 2,Not Applicable
32 Diphosphonates Phase 3,Phase 1,Phase 2,Not Applicable
33 Methylprednisolone acetate Phase 3
34 Protective Agents Phase 3
35 Prednisolone acetate Phase 3
36 Anti-Inflammatory Agents Phase 3,Not Applicable
37 Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
39 glucocorticoids Phase 3,Phase 1
40 Hormones Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Autonomic Agents Phase 3,Phase 1,Phase 2
42 Antiemetics Phase 3
43 Neuroprotective Agents Phase 3
44 Antirheumatic Agents Phase 3,Phase 2,Phase 1
45 Potassium Channel Blockers Phase 3,Phase 2,Not Applicable
46 3,4-diaminopyridine Phase 3,Phase 2,Not Applicable
47 Antineoplastic Agents, Hormonal Phase 3,Phase 2
48 Immunosuppressive Agents Phase 3,Phase 2,Not Applicable
49 Immunoglobulins Phase 3,Phase 1,Phase 2
50 Antibodies Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 75)
# Name Status NCT ID Phase Drugs
1 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
2 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
3 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
4 Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer Unknown status NCT00326820 Phase 3 ibandronate sodium;zoledronic acid;Zolendronic Acid
5 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
6 Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone Completed NCT00003884 Phase 3 zoledronic acid
7 Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) Completed NCT02970162 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
8 A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Completed NCT01377922 Phase 3 Amifampridine Phosphate;Placebo
9 A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases Completed NCT02153398 Phase 3 D961H sachet 10 mg;D961H capsule 10mg;D961H capsule 20 mg
10 Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome Completed NCT00079833 Phase 3 Esomeprazole magnesium (Nexium)
11 Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes Recruiting NCT02562066 Phase 3 amifampridine phosphate;Placebo
12 Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) Recruiting NCT01868269 Phase 3 Dexamethasone acetate;dexamethasone and cyclophosphamide;dexamethasone and rituximab
13 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
14 S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone Withdrawn NCT00301886 Phase 3 ibandronate;zoledronate
15 Ephedrine for the Treatment of Congenital Myasthenia Unknown status NCT00541216 Phase 1, Phase 2 Ephedrine
16 Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma Unknown status NCT00202930 Phase 2 anti-CD20 (Rituximab)
17 Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases Completed NCT00060138 Phase 1, Phase 2 zoledronic acid
18 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
19 Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome Completed NCT01511978 Phase 2 Continuous 3,4-DAP;Taper 3,4-DAP to Placebo
20 MC-5A for Chemotherapy Induced Peripheral Neuropathy Completed NCT01261780 Phase 2 Sham device
21 Effectiveness of Rituximab in Pediatric OMS Patients. Completed NCT00244361 Phase 1, Phase 2 rituximab
22 Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Completed NCT00896454 Phase 2 denosumab
23 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Completed NCT02468193 Phase 2 Osilodrostat
24 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
25 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
26 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
27 YF476 and Type II Gastric Carcinoids Enrolling by invitation NCT02454075 Phase 2 YF476
28 Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis Not yet recruiting NCT03274375 Phase 2 IA session;Rituximab
29 IVIG Treatment for Refractory Immune-Related Adult Epilepsy Terminated NCT01545518 Phase 2 IVIG
30 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
31 SOM230 Ectopic ACTH-producing Tumors Withdrawn NCT02780882 Phase 2 Pasireotide
32 Central Pain Study for ABX-1431 Completed NCT03138421 Phase 1 ABX-1431 HCl;Placebo
33 Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes Completed NCT01203592 Phase 1 Albuterol
34 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1 Rituximab
35 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1 Ublituximab
36 One Week Comparison Study of PTH and PTHrP Infusions Withdrawn NCT01333267 Phase 1 Parathyroid Hormone-related Protein (1-36);parathyroid hormone (1-34);PTH (1-34) and PTHrP (1-36)
37 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
38 Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia Unknown status NCT01660308
39 Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone Unknown status NCT00458796 Not Applicable zoledronic acid
40 Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in China Unknown status NCT02559089
41 Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing Area Unknown status NCT02443350
42 Immunotherapy of the Paraneoplastic Syndromes Completed NCT00378326 Not Applicable Tacrolimus
43 Studies of Neurological Paraneoplastic Syndromes Completed NCT00587106
44 One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study Completed NCT00580788 Early Phase 1 PTHrP (1-36)
45 Clinical Trial of a Serious Game for Individuals With SCI/D Completed NCT02341950 Not Applicable
46 Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis Completed NCT01865578 Not Applicable
47 Pregnancy Outcomes in Congenital Myasthenie Syndrome Completed NCT01474980
48 Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome Completed NCT00806182
49 Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome Completed NCT00004832 Not Applicable 3,4-diaminopyridine
50 The Acute Effect of Coffee Consumption on Stomach, Self-reported Gastrointestinal Symptoms and Stress. Completed NCT02253628 Not Applicable

Search NIH Clinical Center for Paraneoplastic Syndromes

Genetic Tests for Paraneoplastic Syndromes

Anatomical Context for Paraneoplastic Syndromes

MalaCards organs/tissues related to Paraneoplastic Syndromes:

41
Lung, T Cells, Colon, Prostate, Thyroid, B Cells, Myeloid

Publications for Paraneoplastic Syndromes

Articles related to Paraneoplastic Syndromes:

(show top 50) (show all 316)
# Title Authors Year
1
Paraneoplastic syndromes in ophthalmology. ( 29784239 )
2018
2
Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma. ( 29429069 )
2018
3
Paraneoplastic, Syndromes ( 29939667 )
2018
4
Advanced-Stage Thymoma Associating Multiple Paraneoplastic Syndromes with Good Response to Oral Corticosteroids and Topical Tacrolimus. ( 29887166 )
2018
5
Neuroimmunology of OMS and ANNA-1/anti-Hu paraneoplastic syndromes in a child with neuroblastoma. ( 29318181 )
2018
6
Endocrine paraneoplastic syndromes in lung cancer. ( 29968234 )
2018
7
Uncommon reasons of the digestive tract-related paraneoplastic syndromes in children with neuroblastic tumors: three case reports. ( 29692663 )
2018
8
Beyond the Dual Paraneoplastic Syndromes of Small-Cell Lung Cancer with ADH and ACTH Secretion: A Case Report with Literature Review and Future Implications. ( 30498610 )
2018
9
Neurological paraneoplastic syndromes: an update. ( 30124520 )
2018
10
Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms. ( 30280284 )
2018
11
Immunopathogenesis of ophthalmological paraneoplastic syndromes: Recent findings. ( 30289210 )
2018
12
Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study. ( 28767671 )
2017
13
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes. ( 28285701 )
2017
14
Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. ( 29191778 )
2017
15
Much More than Trousseau Syndrome. The Broad Spectrum of the Pancreatic Paraneoplastic Syndromes. ( 28160197 )
2017
16
Rheumatic paraneoplastic syndromes - A clinical link between malignancy and autoimmunity. ( 28736272 )
2017
17
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions. ( 28838389 )
2017
18
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system. ( 28285700 )
2017
19
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature. ( 28285683 )
2017
20
Paraneoplastic syndromes associated with gynecological cancers: A systematic review. ( 28655412 )
2017
21
Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles. ( 28838388 )
2017
22
Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. ( 27177440 )
2016
23
Comments on Kristensen et al.: Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients. ( 26666237 )
2016
24
Intrathecal synthesis of onconeural antibodies in patients with paraneoplastic syndromes. ( 26711581 )
2016
25
Paraneoplastic syndromes revealing ovarian teratoma in young and menopausal women: report of two cases. ( 27795759 )
2016
26
Reply to: "Comments on Kristensen et al.: Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients": By BetA1l Vatankulu, Sabire Yilmaz Aksoy, Sait Sager, Metin HalaAs. ( 26669307 )
2016
27
The lung cancer nurse role in the management of paraneoplastic syndromes in lung cancer. ( 27413699 )
2016
28
Autoantibody diversity in paraneoplastic syndromes and related disorders: The need for a more guided screening approach. ( 27287529 )
2016
29
Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy. ( 26914818 )
2016
30
Paraneoplastic Syndromes in Neuro-Ophthalmology. ( 26172160 )
2015
31
Update on neurological paraneoplastic syndromes. ( 26335665 )
2015
32
Paraneoplastic cerebellar ataxia and the paraneoplastic syndromes. ( 25829659 )
2015
33
A rare thymoma case with seven paraneoplastic syndromes. ( 26770603 )
2015
34
Paraneoplastic syndromes in olfactory neuroblastoma. ( 26199564 )
2015
35
Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients. ( 26194717 )
2015
36
Different Kinds of Paraneoplastic Syndromes in Childhood Neuroblastoma. ( 26199695 )
2015
37
Paraneoplastic Syndromes in Palliative Care: A literature review from a nursing perspective. ( 26514024 )
2015
38
Paraneoplastic syndromes: the way to an early diagnosis of lung cancer. ( 26506668 )
2015
39
Hyperamylasaemia and dual paraneoplastic syndromes in small cell lung cancer. ( 24048720 )
2014
40
Lung squamous carcinoma with two paraneoplastic syndromes -Dermatomyositis and Lambert-Eaton myasthenic syndrome. ( 25335449 )
2014
41
Paraneoplastic syndromes in patients with laryngeal neuroendocrine carcinomas: clinical manifestations and prognostic significance. ( 25351497 )
2014
42
Ectopic Cushing syndrome secondary to metastatic medullary thyroid cancer in a child with multiple endocrine neoplasia syndrome type 2B: clues to early diagnosis of the paraneoplastic syndromes. ( 24859505 )
2014
43
Paraneoplastic syndromes in rheumatology. ( 25136782 )
2014
44
Ectopic Cushing and other paraneoplastic syndromes in thoracic neuroendocrine tumors. ( 25065928 )
2014
45
Prognostic role and significance of paraneoplastic syndromes in hepatocellular carcinoma. ( 24480222 )
2014
46
Multiple paraneoplastic syndromes revealing non-small cell lung carcinoma. ( 25838865 )
2014
47
Paraneoplastic syndromes associated with lung cancer. ( 25114839 )
2014
48
Neurological paraneoplastic syndromes in lung cancer patients. ( 22836651 )
2013
49
Update on clinical and mechanistic aspects of paraneoplastic syndromes. ( 24052434 )
2013
50
Epidemiology and prognosis of paraneoplastic syndromes in hepatocellular carcinoma. ( 24396608 )
2013

Variations for Paraneoplastic Syndromes

Expression for Paraneoplastic Syndromes

Search GEO for disease gene expression data for Paraneoplastic Syndromes.

Pathways for Paraneoplastic Syndromes

Pathways related to Paraneoplastic Syndromes according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.32 FGF23 IL1B IL6
2
Show member pathways
11.79 FGF23 IL1B IL6
3 11.66 FGF23 PTHLH
4 11.65 IL1B IL6
5 11.62 IL1B IL6
6
Show member pathways
11.62 FGF23 IL1B IL6
7 11.6 IL1B IL6
8 11.59 IL1B IL6
9 11.56 IL1B IL6
10 11.53 IL1B IL6
11 11.46 IL1B IL6
12 11.45 IL1B IL6
13 11.42 IL1B IL6
14 11.36 IL1B IL6
15
Show member pathways
11.35 IL1B IL6
16 11.28 IL1B IL6
17 11.2 IL1B IL6
18 11.18 IL1B IL6
19 11.16 IL1B IL6
20 11.11 IL1B IL6
21 10.91 IL1B IL6
22 10.87 IL1B IL6
23 10.8 IL1B IL6
24 10.67 FGF23 IL1B IL6
25 10.66 IL1B IL6
26 10.45 IL1B IL6
27 10.09 IL1B IL6

GO Terms for Paraneoplastic Syndromes

Cellular components related to Paraneoplastic Syndromes according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 8.92 FGF23 IL1B IL6 PTHLH

Biological processes related to Paraneoplastic Syndromes according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.65 FGF23 IL1B IL6
2 positive regulation of cell proliferation GO:0008284 9.63 IL1B IL6 PTHLH
3 negative regulation of cell proliferation GO:0008285 9.5 IL1B IL6 PTHLH
4 response to glucocorticoid GO:0051384 9.43 IL1B IL6
5 positive regulation of T cell proliferation GO:0042102 9.4 IL1B IL6
6 positive regulation of interleukin-6 production GO:0032755 9.37 IL1B IL6
7 negative regulation of neurogenesis GO:0050768 9.26 IL1B IL6
8 positive regulation of glial cell proliferation GO:0060252 9.16 IL1B IL6
9 positive regulation of neuroinflammatory response GO:0150078 8.96 IL1B IL6
10 regulation of signaling receptor activity GO:0010469 8.92 FGF23 IL1B IL6 PTHLH

Sources for Paraneoplastic Syndromes

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....